title: The Alzheimer disease market.
authors.affiliation: IMS Health, 210 Pentonville Road, London, N1 9JY, UK.
authors.forename: XiaoXiao
authors.initials: X
authors.lastname: Qian
authors.affiliation: IMS Health, 210 Pentonville Road, London, N1 9JY, UK.
authors.forename: Bashar
authors.initials: B
authors.lastname: Hamad
authors.affiliation: IMS Health, 210 Pentonville Road, London, N1 9JY, UK.
authors.forename: Gus
authors.initials: G
authors.lastname: Dias-Lalcaca
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy*; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors; D055808:Drug Discovery; D006801:Humans; D000067759:Receptor for Advanced Glycation End Products / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000067759:Receptor for Advanced Glycation End Products; C000600266:aducanumab; C571128:gantenerumab; D053829:Amyloid Precursor Protein Secretases; D016282:Aspartic Acid Endopeptidases; C509280:BACE1 protein, human